Does Vonoprazan Cause Hypertension?
Hypertension is a recognized adverse event with vonoprazan, though it occurs infrequently (reported in <2% to 7.5% of patients depending on duration of exposure), and blood pressure monitoring is specifically recommended during treatment. 1, 2
Evidence from FDA Drug Labeling
The FDA prescribing information for vonoprazan explicitly documents hypertension as an adverse reaction. In clinical trials for H. pylori treatment, hypertension was the most common adverse reaction leading to treatment discontinuation (0.6%) 1. The drug label lists hypertension among adverse reactions identified across multiple clinical trials for erosive esophagitis and non-erosive GERD 1.
Clinical Trial Data on Blood Pressure Effects
Blood pressure monitoring is specifically mandated during vonoprazan therapy based on observed increases in clinical trials 2:
- Post-hoc analyses from the phase 3 True North trial in ulcerative colitis patients showed small increases in mean blood pressure that stabilized over time with up to 1 year of treatment
- Hypertension occurred in <2% of UC patients receiving vonoprazan, with no cases resulting in treatment discontinuation 2
- In multiple sclerosis patients treated for up to 5 years, a slightly higher incidence of 7.5% was reported 2
Recommended Monitoring Protocol
Based on expert consensus and clinical trial experience 2:
- Patients with pre-existing hypertension: Monitor blood pressure weekly for the first month of treatment
- All patients: Check blood pressure at 3 months (when changes were first observed in trials), then every 6 months if stable
- Symptomatic patients: Monitor if symptoms of hypertension develop at any time
- Monitoring can be performed by gastroenterologists or in collaboration with primary care physicians
Pharmacovigilance Data
Real-world post-marketing surveillance supports the clinical trial findings. A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database identified hypertension as a significant safety signal with vonoprazan, suggesting the need for enhanced monitoring in clinical practice 3. However, an integrated analysis of 14 clinical trials (5,318 patients on vonoprazan) found the overall safety profile comparable to PPIs, with no specific emphasis on elevated hypertension rates compared to comparators 4.
Clinical Context and Comparison
The hypertension risk with vonoprazan appears lower than with many other medications known to elevate blood pressure. For context, the 2020 International Society of Hypertension guidelines document that NSAIDs increase blood pressure by 3/1 mmHg, SNRIs by 2/1 mmHg, and oral contraceptives by 6/3 mmHg 5. Vonoprazan's blood pressure effects appear modest by comparison, with small mean increases that stabilize over time.
Important Caveats
- The mechanism underlying vonoprazan-associated hypertension is not fully elucidated in the available evidence
- Individual patient responses may vary, particularly in elderly patients, those with baseline hypertension, or those on multiple antihypertensive medications
- Pre-existing well-controlled hypertension is not a contraindication to vonoprazan use, provided appropriate monitoring is implemented 2
- Drug interactions with calcium channel blockers (particularly amlodipine) may complicate blood pressure management and require additional attention 6
In summary, while vonoprazan can cause hypertension, the incidence is low (<2-7.5%), the magnitude of blood pressure increase is generally modest, and the risk is manageable with appropriate monitoring. This should not preclude vonoprazan use in patients who would otherwise benefit from its superior acid suppression, but does necessitate systematic blood pressure surveillance.